A Comparative Study of the Effects of Clozapine and Risperidone Monotherapy on Lipid Profile in Nigerian Patients with Schizophrenia

Idonije, O. B.; Festus, O.; Akpamu, U; Okhiai, O; Iribhogbe, Osede Ignis; Iyalomhe, Godfrey B. S.

doi:10.3923/ijp.2012.169.176

Cited by 8 publications

(8 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The findings in the present study are similar to that of a Nigerian study [ 17 ] which compared the effects of clozapine and risperidone on lipid profiles. At the end of six weeks there was a significant increase in serum TC, LDL, TG and a significant decrease in HDL in both treatment groups compared to controls.…”

Section: Discussionsupporting

confidence: 90%

See 1 more Smart Citation

Dyslipidaemia and Medical Outcome (Health Related Quality of Life) in Patients with Schizophrenia Taking Antipsychotics in Enugu, Nigeria

et al. 2017

View full text Add to dashboard Cite

Aim. Determine association between use (and type) of antipsychotics and dyslipidaemia in newly diagnosed schizophrenia patients attending Federal Neuropsychiatric Hospital, Enugu. Methods. From sixty antipsychotic naive patients with schizophrenia and sixty first-degree relatives matched for gender and age, fasting blood lipid profiles were measured at baseline and after twelve weeks. Medical Outcome Study Short Form General Health Survey was administered to patients on both occasions. Fasting lipid profile changes of both groups were compared. Results. Mean endpoint of total cholesterol (TC), low density lipoprotein (LD), and triglycerides (TG) in mmol/l for cases was significantly higher than initial values (TC 4.5 versus 4.3, t = 4.3, p < 0.0001), (LDL 2.8 versus 2.6, t = 14.3, p < 0.0001), and (TG 1.3 versus 1.0, t = 12.1, p < 0.0001). Mean endpoint of high density lipoprotein (HDL) in mmol/l for cases was significantly lower than initial values (1.1 versus 1.2, t = 12.1, p < 0.0001). Prevalence of dyslipidaemia for cases was 13%. Mean endpoint of TC, LDL, TG, and HDL in mmol/l for controls was not significantly different from initial values (TC 4.30 versus 4.27, t = 1.09, p = 0.279), (LDL 2.49 versus 2.46, t = 1.28, p = 0.205), (TG 0.96 versus 0.94, t = 1.27, p = 0.207), and (HDL 1.37 versus 1.38, t = 1.61, p = 0.113). Subjects on atypical antipsychotics had higher risk for dyslipidaemia. Conclusion. Use of antipsychotics was significantly associated with dyslipidaemia.

show abstract

Section: Discussionsupporting

confidence: 90%

“…It has been shown that patients with schizophrenia treated for years with antipsychotic medication may develop tolerance to the effects of antipsychotics on lipid levels, so measurements of postprandial levels in addition to fasting levels may be helpful in identifying metabolic effects among such patients [17]. …”

Section: Discussionmentioning

confidence: 99%

Dyslipidaemia and Medical Outcome (Health Related Quality of Life) in Patients with Schizophrenia Taking Antipsychotics in Enugu, Nigeria

et al. 2017

View full text Add to dashboard Cite

show abstract

“…It was shown that risperidone treated group had a significant increase in cholesterol level after 6 weeks compared with clozapine. 16 In our study, cholesterol level increased significantly after 12 weeks in patients treated with risperidone. Divergent results have been found about the quetiapine induced hyperlipidaemia.…”

Section: Discussionmentioning

confidence: 70%

“…[13][14] Abnormalities in lipid metabolism have been shown to occur in patients treated with clozapine, olanzapine, quetiapine, risperidone or haloperidol. Olanzapine has been associated with significant increase in serum triglyceride levels and severe hyperlipidaemia 15,16 . According to a recent US consensus statement, the SGAs vary in their propensity to cause obesity, hyper glycaemia and hyperlipidaemia, with clozapine and olanzapine showing the greatest effects, risperidone and quetiapine having intermediate effects, and aripiprazole and ziprasidone have lowest effects.…”

Section: Introductionmentioning

confidence: 99%

“…The findings are consistent with openlabel and retrospective data demonstrating a greater association of olanzapine and clozapine treatment than risperidone with increases in cholesterol and triglycerides; 25 Significantly higher LDL-C levels in risperidone treated group was found compared to clozapine. 16 Dyslipidaemia caused by SGAs in this study could be related to insulin resistance developing after weight gain and is associated with dyslipidaemic triad, "an increase in TG and LDL-C and a decrease in HDL-C" . 26 Divergent results regarding hyperglycaemia and dyslipidaemia with the use of different members of SGAs could be due to variation in sample size, duration of treatment, severity of disease, race, social class and extent of weight gain.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Metabolic risk factor profile in patients on treatment with second generation antipsychotics

Zahan

Akhter

Mullick

et al. 2016

Bangladesh Med Res Counc Bull

View full text Add to dashboard Cite

The second generation antipsychotic agents, although exhibit superior safety profile, is associated with metabolic adverse effects including weight gain, diabetes mellitus and hyperlipidaemia. These adverse effects are not only the risk factors for cardiovascular disease and diabetes mellitus but may also impair patient's adherence to treatment. However, different member of second generation antipsychotics differ in their extent of metabolic adverse effects. The aim of the study was to evaluate the association between olanzapine, risperidone or quetiapine treatment and body mass index, blood pressure, diabetes mellitus and hyperlipidaemia in patients with Schizophrenia and Bipolar Disorder. Forty-four cases of Schizophrenia and Bipolar Disorder diagnosed with DSM-IV criteria were selected according to inclusion and exclusion criteria. Body weight, body mass index and blood pressure were measured at baseline, at the end of 4th, 8th and 12th weeks of treatment. Blood samples were collected to measure blood glucose and serum lipid profile at baseline and at the end of 4th, 8th and 12th weeks in the study group receiving treatment (olanzapine 20-30 mg/day, risperidone 4-16 mg/day and quetiapine 300-800 mg/day) after overnight fasting. Therapeutic use of olanzapine and risperidone in Schizophrenia and Bipolar Disorder for a period of 4th, 8th and 12th weeks was associated with significant increase in body weight and body mass index. Quetiapine did not cause significant changes in body weight and body mass index after 4 and 8 weeks. However, after 12 weeks treatment, body mass index increased significantly. Olanzapine, risperidone and quetiapine increased the blood glucose level significantly after 8 and 12 weeks treatment. Olanzapine and risperidone elevated the serum cholesterol, triglyceride and low density lipoprotein levels significantly after 4, 8 and 12 weeks. But quetiapine showed no significant change in lipid profile. However, olanzapine and risperidone significantly increased triglyceride level after 8 and 12 weeks. Amongst three drugs, quetiapine treatment increased high density lipoprotein level. Our study revealed that quetiapine treatment is associated with less risk of dyslipidaemia.

show abstract

Antipsychotic Drugs

Chue¹,

Neagu²

2014

Side Effects of Drugs Annual

View full text Add to dashboard Cite

A Comparative Study of the Effects of Clozapine and Risperidone Monotherapy on Lipid Profile in Nigerian Patients with Schizophrenia

Cited by 8 publications

References 0 publications

Dyslipidaemia and Medical Outcome (Health Related Quality of Life) in Patients with Schizophrenia Taking Antipsychotics in Enugu, Nigeria

Dyslipidaemia and Medical Outcome (Health Related Quality of Life) in Patients with Schizophrenia Taking Antipsychotics in Enugu, Nigeria

Metabolic risk factor profile in patients on treatment with second generation antipsychotics

Antipsychotic Drugs

Contact Info

Product

Resources

About